Innogene이노진
344860 · KOSDAQ · ₩344860 · 이노진
₩1,483▲ ₩18 (1.23%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | ₩8.2B | ₩8.9B | ₩10B | ₩9.1B |
| Cost of sales | ₩2B | ₩2.3B | ₩2.8B | ₩2.4B |
| Gross profit | ₩6.2B | ₩6.6B | ₩7.3B | ₩6.8B |
| Operating income | ₩4.5M | ₩630M | ₩1.2B | ₩1.5B |
| Net income | ₩288M | ₩945M | ₩1.4B | ₩1.3B |
| Net income to shareholders | ₩288M | ₩945M | ₩1.4B | ₩1.3B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total assets | ₩15B | ₩18B | ₩17B | ₩7.9B |
| Current assets | ₩13B | ₩16B | ₩15B | ₩6.2B |
| Cash and equivalents | ₩1.6B | ₩1.3B | ₩1.3B | ₩1.4B |
| Total liabilities | ₩939M | ₩933M | ₩1.2B | ₩1.2B |
| Current liabilities | ₩920M | ₩933M | ₩1.1B | ₩1.2B |
| Borrowings | ₩516M | ₩420M | ₩469M | ₩408M |
| Total equity | ₩14B | ₩17B | ₩16B | ₩6.7B |
| Shareholders' equity | ₩14B | ₩17B | ₩16B | ₩6.7B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Cash from operations | ₩704M | ₩809M | ₩2.2B | ₩585M |
| Capital spending | ₩152M | ₩0 | — | — |
| Free cash flow | ₩552M | ₩809M | ₩2.2B | ₩585M |
| Dividends paid | ₩957M | ₩359M | — | — |
Consolidated where available. Amounts in won.
Also known as: Innogene / 이노진 / 344860 / KRX:344860
Source: KRX statistical information